PROCESS FOR CREATING SOLID DISPERSIONS

Abstract

A process for producing a solid dispersion of a material by spraying the material onto a fluidized cloud of carrier particles in a fluid bed. The fluidized cloud of carrier particles is formed by adding a solid or liquid carrier to a fluid bed. The material to be sprayed is in a liquid or gas form. The process is especially applicable to the formation of amorphous solid powder pharmaceutical ingredients.

Claims

1. A process for producing a solid dispersion comprising a material and a carrier, the steps of the process comprising: (a) fluidizing a solid or liquid form of the carrier in a fluid bed to form a fluidized cloud of carrier particles; and (b) spraying a liquid or gas form of the material onto the fluidized cloud of particles to form the solid dispersion.

2. The process of claim 1 where the material comprises a solution, emulsion or suspension.

3. The process of claim 1 where the material comprises a pharmaceutical ingredient, cosmetic, foodstuff, dietary supplement, flavoring, fragrance or specialty chemical.

4. The process of claim 1 where the carrier comprises a polysaccharide, a mineral or derivative comprising silicon, aluminum and/or magnesium, or a mixture thereof.

5. The process of claim 4 where the carrier comprises microcrystalline cellulose, alumina, clay, talc, kaolin, bentonite, hectorite, silicon dioxide, calcium silicate, colloidal magnesium-aluminum silicate, magnesium trisilicate, magnesium aluminometasilicate, aluminum hydroxide, magnesium hydroxide, magnesium oxide, or a mixture thereof.

6. The process of claim 5 where the silicon dioxide is fumed, colloidal, precipitated, milled, or a mixture thereof.

7. The process of claim 4 where the carrier has the following properties: (a) a mean particle diameter of about 10-200 microns; (b) a mean particle size of about 150 microns; (c) a BET surface area of about 40-400 m.sup.2/g; and (d) a pore volume of about 0.5-2.8 mL/g.

8. The process of claim 2 where the material comprises a pharmaceutical active ingredient and the carrier comprises a polysaccharide, a mineral or derivative comprising silicon, aluminum, and/or magnesium, or a mixture thereof.

9. The process of claim 8 where the solid dispersion comprises a void volume of less than about 70%.

10. The process of claim 8 where the active ingredient comprises a solution.

11. The process of claim 10 where the solution further comprises a pharmaceutical excipient.

12. The process of claim 10 where the solution comprises a solvent selected from the group consisting of water, acetone, ethyl acetate, dichloromethane, methanol ethanol, isopropanol, and a mixture thereof.

13. The process of claim 2 where the fluid bed contains a nozzle spraying configuration comprising a top spray, bottom spray or tangential/radial spray.

14. The process of claim 2 further comprising the step of compressing the solid dispersion into a tablet.

15. The process of claim 2 where the solid dispersion comprises a substantially amorphous form.

16. A process for producing a solid dispersion comprising a pharmaceutical active ingredient and a silica carrier, the steps of the process comprising: (a) mixing a solid or gas form of the solid pharmaceutical active ingredient in a solvent to form a solution, suspension or emulsion; (b) fluidizing a solid or liquid form of the silica carrier in a fluid bed to form a fluidized cloud of silica carrier particles; and (c) spraying the solution, suspension or emulsion onto the fluidized cloud of silica carrier particles to form the solid dispersion.

17. The process of claim 16 where the silica carrier has the following properties: (a) a mean particle diameter of about 10-200 microns; (b) a mean particle size of about 150 microns; (c) a BET surface area of about 40-400 m.sup.2/g; and (d) a pore volume of about 0.5-2.8 mL/g.

18. The process of claim 16 where the solid dispersion comprises a void volume of less than about 70%.

19. The process of claim 16 where the solid dispersion comprises a substantially amorphous form.

20. A process for producing a solid dispersion comprising a pharmaceutical active ingredient and a silica carrier, the steps of the process comprising: (a) mixing a solid or gas form of the pharmaceutical active ingredient in a solvent to form a solution, suspension or emulsion; (b) fluidizing a solid or liquid form of the silica carrier in a fluid bed to form a fluidized cloud of silica carrier particles; and (c) spraying the solution, suspension or emulsion onto the fluidized cloud of silica carrier particles to form the solid dispersion, wherein, the silica carrier has the following properties: (a) a mean particle diameter of about 10-200 microns; (b) a mean particle size of about 150 microns; (c) a BET surface area of about 40-400 m.sup.2/g; and (d) a pore volume of about 0.5-2.8 mL/g; and the solid dispersion comprises a void volume of less than about 70%.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0027] The following drawings form part of the specification and are included to further demonstrate certain embodiments or various aspects of the invention. In some instances, embodiments of the invention can be best understood by referring to the accompanying drawings in combination with the detailed description presented herein. The description and accompanying drawings may highlight a certain specific example, or a certain aspect of the invention. However, one skilled in the art will understand that portions of the example or aspect may be used in combination with other examples or aspects of the invention. The features, objects and advantages will become more readily apparent when consideration is given to the detailed description below. Such detailed description makes reference to the following drawings.

[0028] FIG. 1. An illustration of a silicon dioxide particle pore volume using the processing method of Example 3.

[0029] FIG. 2. An illustration of a silicon dioxide particle pore volume using the processing method of Example 1.

[0030] FIG. 3. A photograph of the saturated solution of Example 2.

[0031] FIG. 4. X-ray powder diffraction patterns of commercial crystalline curcumin and an amorphous solid dispersion product of curcumin using the processing method of Example 5.

[0032] FIG. 5. Dissolution profiles of a commercial crystalline curcumin capsule and an amorphous solid dispersion tablet of curcumin using the processing method of Example 6.

[0033] FIG. 6. Focused beam reflectance measurement (FBRM) total count profile of a commercial crystalline curcumin capsule and an amorphous solid dispersion tablet of curcumin using the processing method of Example 6.

[0034] FIG. 7. X-ray powder diffraction pattern of an amorphous solid dispersion of curcumin using the spray drying method of Example 8.

[0035] FIG. 8. Photographs of storage stability testing for an amorphous solid dispersion product of curcumin using the processing method of Example 5 and an amorphous solid dispersion product of curcumin using the processing method of Example 8.

[0036] While the present invention is susceptible to various modifications and alternative forms, exemplary embodiments thereof are shown by way of example in the drawings and are herein described in detail. It should be understood, however, that the description of exemplary embodiments is not intended to limit the invention to the particular forms disclosed, but on the contrary, the intention is to cover all modifications, equivalents and alternatives falling within the spirit and scope of the invention as defined by the embodiments herein and the claims below. Reference should therefore be made to the embodiments and claims for interpreting the scope of the invention.

DETAILED DESCRIPTION

[0037] We have developed a new process to create a solid dispersion without the need for spray drying equipment. The process comprises the utilization of a fluid bed system to form a fluidized cloud of carrier (e.g., silicon dioxide) particles and the spraying of a material onto the carrier cloud for the preparation of a solid dispersion comprising the material loaded onto the carrier. The process particularly described and exemplified herein is particularly useful for the production of pharmaceutical compositions. The pharmaceutical solid products produced by our process are typically substantially or fully amorphous, though partially and fully crystalline products may also be produced. Additionally, the process can be applied to any field that employs the use of a solid powder dispersion, such as foodstuffs, flavorings, dietary supplements, fragrances, cosmetics, coatings, specialty chemicals and specialty materials. The processes described herein are useful for increasing yield and processing times without the need for specialized processing equipment and/or secondary drying equipment, such as spray drying.

Definitions

[0038] The following definitions are included to provide a clear and consistent understanding of the specification and claims. As used herein, the recited terms have the following meanings. All other terms and phrases used in this specification have their ordinary meanings as one of skill in the art would understand. Such ordinary meanings may be obtained by reference to technical dictionaries, such as Hawley's Condensed Chemical Dictionary 14.sup.th Edition, by R. J. Lewis, John Wiley & Sons, New York, N.Y., 2001.

[0039] References in the specification to one embodiment, an embodiment, etc., indicate that the embodiment described may include a particular aspect, feature, structure, moiety, or characteristic, but not every embodiment necessarily includes that aspect, feature, structure, moiety, or characteristic. Moreover, such phrases may, but do not necessarily, refer to the same embodiment referred to in other portions of the specification. Further, when a particular aspect, feature, structure, moiety, or characteristic is described in connection with an embodiment, it is within the knowledge of one skilled in the art to affect or connect such aspect, feature, structure, moiety, or characteristic with other embodiments, whether or not explicitly described.

[0040] The singular forms a, an, and the include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to a compound includes a plurality of such compounds, so that a compound X includes a plurality of compounds X. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for the use of exclusive terminology, such as solely, only, and the like, in connection with any element described herein, and/or the recitation of claim elements or use of negative limitations.

[0041] The term and/or means any one of the items, any combination of the items, or all of the items with which this term is associated. The phrase one or more is readily understood by one of skill in the art, particularly when read in context of its usage. For example, the phrase can mean one, two, three, four, five, six, ten, 100, or any upper limit approximately 10, 100, or 1000 times higher than a recited lower limit.

[0042] As will be understood by the skilled artisan, all numbers, including those expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth, are approximations and are understood as being optionally modified in all instances by the term about. These values can vary depending upon the desired properties sought to be obtained by those skilled in the art utilizing the teachings of the descriptions herein. It is also understood that such values inherently contain variability necessarily resulting from the standard deviations found in their respective testing measurements. When values are expressed as approximations, by use of the antecedent about, it will be understood that the particular value without the modifier about also forms a further aspect.

[0043] The terms about and approximately are used interchangeably. Both terms can refer to a variation of 5%, 10%, 20%, or 25% of the value specified. For example, about 50 percent can in some embodiments carry a variation from 45 to 55 percent, or as otherwise defined by a particular claim. For integer ranges, the term about can include one or two integers greater than and/or less than a recited integer at each end of the range. Unless indicated otherwise herein, the terms about and approximately are intended to include values, e.g., weight percentages, proximate to the recited range that are equivalent in terms of the functionality of the individual ingredient, composition, or embodiment. The terms about and approximately can also modify the end-points of a recited range as discussed above in this paragraph.

[0044] As will be understood by the skilled artisan, all numbers, including those expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth, are approximations and are understood as being optionally modified in all instances by the term about. These values can vary depending upon the desired properties sought to be obtained by those skilled in the art utilizing the teachings of the descriptions herein. It is also understood that such values inherently contain variability necessarily resulting from the standard deviations found in their respective testing measurements.

[0045] As will be understood by one skilled in the art, for any and all purposes, particularly in terms of providing a written description, all ranges recited herein also encompass any and all possible sub-ranges and combinations of sub-ranges thereof, as well as the individual values making up the range, particularly integer values. A recited range (e.g., weight percentages or carbon groups) includes each specific value, integer, decimal, or identity within the range. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, or tenths. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will also be understood by one skilled in the art, all language such as up to, at least, greater than, less than, more than, or more, and the like, include the number recited and such terms refer to ranges that can be subsequently broken down into sub-ranges as discussed above. In the same manner, all ratios recited herein also include all sub-ratios falling within the broader ratio. Accordingly, specific values recited for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for radicals and substituents.

[0046] One skilled in the art will also readily recognize that where members are grouped together in a common manner, such as in a Markush group, the invention encompasses not only the entire group listed as a whole, but each member of the group individually and all possible subgroups of the main group. Additionally, for all purposes, the invention encompasses not only the main group, but also the main group absent one or more of the group members. The invention therefore envisages the explicit exclusion of any one or more of members of a recited group. Accordingly, provisos may apply to any of the disclosed categories or embodiments whereby any one or more of the recited elements, species, or embodiments, may be excluded from such categories or embodiments, for example, for use in an explicit negative limitation.

[0047] The term contacting refers to the act of touching, making contact, or of bringing to immediate or close proximity, including at the cellular or molecular level, for example, to bring about a physiological reaction, a chemical reaction, or a physical change, e.g., in a solution, in a reaction mixture, in vitro, or in vivo.

[0048] An effective amount refers to an amount effective to bring about a recited effect, such as an amount necessary to form products in a reaction mixture. Determination of an effective amount is typically within the capacity of persons skilled in the art, especially in light of the detailed disclosure provided herein. The term effective amount is intended to include an amount of a compound or reagent described herein, or an amount of a combination of compounds or reagents described herein, e.g., that is effective to form products in a reaction mixture. Thus, an effective amount generally means an amount that provides the desired effect.

[0049] The term substantially as used herein, is a broad term and is used in its ordinary sense, including, without limitation, being largely but not necessarily wholly that which is specified. For example, the term could refer to a numerical value that may not be 100% the full numerical value. The full numerical value may be less by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, or about 20%.

[0050] As used herein, substantially amorphous refers to greater that about 50% of a solid dispersion lack a specific order, shape or form. Substantially amorphous may also refer to greater than 75%, greater than 90%, or greater than about 95% of a solid dispersion, lack a specific order, shape or form. Conversely, substantially crystalline refers to greater that about 50% of solid crystals are of a particular crystalline form. Substantially crystalline may also refer to greater that 75%, greater than 90%, or greater than about 95% of solid crystals, are of a particular crystalline form.

[0051] The term fluidization (fluidizing) as used herein, refers to a process for the conversion of a granular material from a static solid-like state to a dynamic fluid-like state. Utilizing fluid bed technology, fluidization occurs when a fluid (liquid or gas) is passed up through the granular material. When fluidized, a bed of solid particles will behave as a fluid, like a liquid or gas. Thus, fluidization may be utilized to fluidize a solid form of a granular material. A solution, emulsion or suspension of granular material can also be fluidized in a similar manner.

[0052] The art of formulating a solid pharmaceutical composition entails the sophisticated application of multiple scientific disciplinese.g., chemistry, biology, physics, mathematics and materials. One common challenge to the formulator is how best to mix a pharmaceutical active ingredient with an excipient, such as a carrier, to form a homogenous solid composition of the active ingredient. Often, the homogeneity of the final product is less than desired, which can produce deleterious effects.Despite considerable efforts, the loading efficiency of an active ingredient onto a carrier often leads to less than optimal results, such as significant and undesirable void volumes in the final product. Void volumes in solid dispersions are a common defect seen with traditional processes. For example, in a conventional process to mix an active ingredient with a silicon dioxide carrier, the internal pore of a single silicon dioxide carrier particle is filled with a mixture of active ingredient and solvent. When the solvent is evaporated from the particle, a void is left behind in the particle. The void volume is a measurement of the void left behind.

[0053] FIG. 1 provides an illustration of a void commonly seen in a conventional solid pharmaceutical composition comprising a pharmaceutical active ingredient loaded onto a carrier particle. This figure shows a void volume of greater than about 70% after solvent evaporation. This means that the active ingredient is only loaded less than about 30% onto the particle. A void volume can lead to several deleterious effects, such as tablet defects and cracking due to entrapped air in the formulation matrix. A void volume also significantly reduces the quantity of active ingredient that can be loaded onto the particle. The lack of homogeneity caused by a void volume is a serious problem for critical applications, such as delivering a drug in vivo.

[0054] We have addressed these issues by developing a new process (NucleLoad process) for producing a dried solid (e.g., powder) dispersion (NucleLoad solid dispersion) without the need of utilizing any secondary drying equipment, such as a spray dryer. The NucleLoad solid dispersions produced by the NucleLoad process exhibit enhanced physico-chemical properties by providing a more uniform loading of a material into the pores of carrier particles. This is especially useful to create a more efficient loading concentration of a pharmaceutical active ingredient. The NucleLoad processes described herein can efficiently load a solid active pharmaceutical ingredient into the pores of a solid carrier particle and avoid the deficiencies of conventional processes that attempt to do the same.

[0055] In an embodiment, a pharmaceutical active ingredient is dissolved into a solvent with or without additional ingredients and sprayed onto a fluidized cloud of silicon dioxide particles via the use of fluid bed technology. Our process provides for simultaneous wetting, deposition and evaporation of the processing solvent, which allows for an environment that builds up the internal pore structure over time to a substantially full particle. A substantially full pore (e.g., >95%) in a silicon dioxide particle produced by the NucleLoad process is illustrated in FIG. 2. This means the void volume is <5%. Compared to the relatively large void volumes commonly seen with conventional processes (FIG. 1), the small void volumes seen with the NucleLoad process (FIG. 2) can avoid the deleterious effects of significant void volume often seen with solid dispersion products. Utilizing the NucleLoad processes described herein can maximize loading efficiency, which in turn, will minimize void volumes. For example, the loading efficiency on a volume basis may be greater than 30%, greater than 50%, greater than 65%, greater than 75%, greater than 90%, greater than about 95%, or greater than 98%. Conversely, the void volume may be less than 70%, less than 50%, less than 35%, less than 25%, less than 10%, less than about 5%, or less than 2%.

[0056] A composition prepared according to our process can be readily characterized and differentiated from compositions prepared by conventional physical mixtures using standard analytical tools for determining physico-chemical properties. Providing a more homogenous composition brings numerous benefits, such as, a broader therapeutic applicability, a potentiation or synergism of the activity of each of the components of the complex, and/or other enhancement of pharmacokinetic properties.

[0057] In one aspect, the process comprises combining pharmaceutical ingredients in predefined quantities in a suitable medium or carrier and recovering the solid dispersion. In an embodiment, we teach a process for the preparation of a solid dispersion comprising the steps of: (i) forming a solution of each component (e.g., pharmaceutical active ingredient(s) and/or excipient(s)) in an appropriate solvent; (ii) mixing the solutions of step (i) together at a suitable temperature to form a single solution containing all the components; and (iii) isolating a solid dispersion of the solution of step (ii) via a conventional fluid bed. In a particular embodiment, carrier particles are fluidized in a fluid bed and the solution of step (ii) is sprayed onto the fluidized carrier particles. Alternatively, one or more (but less than all) of the individual components may be subjected to steps (ii) and (iii) and a final composition can be formulated via conventional processing afterwards. In other embodiments, an emulsion or suspension is formed instead of a solution in steps (i) and/or (ii). These processes allow one to eschew the use of a spray dryer and its attendant loss of particle into the inlet plenum. A formulator skilled in the art can readily obtain complexes of different molar ratios by adjusting the molar amounts of each component in step (i).

[0058] A pharmaceutical compound is usually combined with a suitable solid carrier, provided that the resulting combination exhibits physical properties that allow it to be more easily formulated than the parent compound. Examples of suitable solid carriers include polysaccharides and minerals or derivatives of silicon (e.g., silicate minerals), aluminum and/or magnesium. In embodiments, suitable solid carriers may comprise finely divided solids, such as kaolin, bentonite, hectorite, colloidal magnesium-aluminum silicate, silicon dioxide, magnesium trisilicate, aluminum hydroxide, magnesium hydroxide, magnesium oxide, microcrystalline cellulose, alumina, clay, talc, and the like. In other embodiments, the solid carrier can comprise calcium silicate (e.g., Zeopharm) and/or magnesium aluminometasilicate (e.g.,)Neusilin.

[0059] Suitable silica derivatives may include, for example, those that are described in international patent application publication number WO 03/037379 and the references cited therein, which are herein incorporated by reference. Typically, these silica derivatives comprise a granular hydrophilic fumed (and/or colloidal) silica that has a mean particle diameter of 10 to 200 microns and a BET surface area of 40 to 400 m.sup.2/g (determined according to DIN 66 131 with nitrogen). The silica derivatives also typically have a pore volume of about 0.5 to 2.8 mL/g, wherein less than about 5% of the overall pore volume has a pore diameter of less than about 5 nm, the remainder being mesopores and macropores. Additionally, the silica derivatives typically have a pH in the range of about 3.6 to about 8.5 and a tamped density of about 220 to about 700 g/L.

[0060] One specific silica material that is particularly useful in the compositions and methods described herein is AEROPERL 300 (fumed/colloidal silica), which is available from Evonik Degussa AG (Dusseldorf, Germany). Other specific silica materials that are particularly useful are Syloid grades available from W. R. Grace and Company (Columbia, Md.). Additionally, other materials having physical and chemical properties similar to the silica materials described herein can also be used. In embodiments of the invention, the silica particles have a mean grain diameter of 20-40 microns. In embodiments of the invention, the silica particles have a BET surface area of at least 150 m.sup.2/g, at least 200 m.sup.2/g, at least 250 m.sup.2/g, or at least 275 m.sup.2/g.

[0061] In the experimental section below, we have utilized carriers in our process having the following properties: [0062] (a) a mean particle diameter of about 10-200 microns; [0063] (b) a mean particle size of about 150 microns; [0064] (c) a BET surface area of about 40-400 m.sup.2/g; and [0065] (d) a pore volume of about 0.5-2.8 mL/g.

[0066] Using the NucleLoad loading processes and silica carriers described herein, we have enhanced the loading efficiency of a pharmaceutical active ingredient onto the silica carrier particles. We have determined that greater than 95% (w/w) of a pharmaceutical active ingredient or a mixture of one or more pharmaceutical active ingredients with excipients can be loaded onto the silica carrier particles. As mentioned above, a high loading capacity is particularly beneficial for pharmaceutical applications.

[0067] As revealed above, fluid bed processing has been utilized in many industries, such as pharmaceutical, foodstuff, petroleum and chemical processing. In the pharmaceutical industry, fluid bed granulation with subsequent fluid bed drying and coating, are useful methods to produce granules for pharmaceutical manufacturing. In the NucleLoad processes described herein, fluid bed technology is used in a novel way to enhance the loading efficiency of one or more compounds and produce a highly loaded solid dispersion product. The fluid beds can handle aqueous solutions, organic solvent solutions (i.e., acetone, isopropanol, ethanol and methanol) and/or suspensions for spraying. The specific processing parameters, selection of processing solvent(s), and ratios of ingredients can be adjusted to create the desired solid dispersion of interest. Examples of commercial fluidized beds for the pharmaceutical industry that may be utilized with the processes described herein are those produced by Robert Bosch Packaging Technology, Inc. (Minnesota, US). Bosch produces various types of nozzle spraying configurations, such as top-spray, Wurster bottom spray, tangential/radial spray and Huttlin bottom spray. The Bosch Solidlab 1 and Solidlab 2 systems are two types of fluid beds that may be utilized with our processes.

[0068] When the starting material to be used in a NucleLoad process is in a solid form, it can be beneficial to first transform the solid into a solution, emulsion or suspension, which is a preferred form for spraying the material into the fluid bed. Conventional methods may be employed to achieve this task, such as the application of heat or the addition of a solvent (e.g., water, acetone, ethyl acetate, dichloromethane, methanol ethanol, isopropanol or a mixture thereof).

[0069] The solid pharmaceutical dispersions produced according to the processes described herein can be used to create many different kinds of pharmaceutical formulations. The solid dispersions can be combined with pharmaceutically acceptable diluents, excipients and/or other carriers, such as lactose, povidone, croscarmellose sodium, microcrystalline cellulose, magnesium stearate, starch, sodium starch glycolate, pregelatinized starch, colloidal silicon dioxide, and the like. Pharmaceutically acceptable salts and solvates may be obtained using standard procedures well known in the art. The solid dispersions can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient, in a variety of forms. The forms can be specifically adapted to a chosen route of administration, e.g., oral or parenteral administration, by intravenous, intramuscular, topical or subcutaneous routes. The solid dispersions described herein may be systemically administered in combination with a pharmaceutically acceptable vehicle, such as an inert diluent or an assimilable edible carrier. For oral administration, compounds can be enclosed in hard or soft-shell gelatin capsules, compressed into tablets, or incorporated directly into the food of a patient's diet. The solid dispersions may also be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. The amount of active ingredient in therapeutically useful compositions can be such that an effective dosage level can be obtained.

[0070] The tablets, troches, pills, capsules, and the like may also contain one or more of the following ingredients: binders, such as gum tragacanth, acacia, corn starch and/or or gelatin; excipients, such as dicalcium phosphate; disintegrating agents, such as corn starch, potato starch, alginic acid, and the like; lubricants, such as magnesium stearate; sweetening agents, such as sucrose, fructose, lactose and/or aspartame; and flavoring agents, such as peppermint, oil of wintergreen and/or cherry flavoring. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil and/or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills or capsules may be coated with gelatin, wax, shellac, sugar, and the like. A syrup or elixir may contain a pharmaceutical active compound with one or more inactive ingredients, such as sucrose and/or fructose as a sweetening agent, methyl and/or propyl parabens as a preservative, and a dye and/or flavoring, such as cherry or orange flavor. Any material used in preparing a unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.

[0071] Formulations may be prepared by conventional procedures well known in the pharmaceutical art. It will be appreciated that the pharmaceutical compositions described herein may be varied according to well-known pharmaceutical techniques to accommodate differing amounts and types of active ingredient. Additionally, the specific ingredients and proportions described herein are for illustrative purposes. Ingredients may be exchanged for suitable equivalents and proportions may be varied, according to the desired properties of the dosage form of interest.

[0072] A skilled artisan in the field of pharmaceutical formulations can utilize the NucleLoad processes described herein to form a high quality solid dispersion, then routinely incorporate the solid dispersion in an appropriate formulation depending on the requirements for product.

[0073] The following Examples are intended to illustrate the above invention and should not be construed as to narrow its scope. One skilled in the art will readily recognize that the Examples suggest many other ways in which the invention could be practiced. It should be understood that numerous variations and modifications may be made while remaining within the scope of the invention.

EXAMPLES

Example 1

Loading of Acetaminophen on Silicon Dioxide Using Bosch Solidlab 1 Fluid Bed (NucleLoad Process)

[0074] An acetaminophen solution was prepared by dissolving 80.25 g of solid acetaminophen (APAP) in 375 g methanol.

[0075] Density of methanol is 0.791 g/mL.

[0076] Solution volume is 474 mL.

[0077] Solution concentration on a volume basis is 80,250 mg/474 mL=169 mg APAP/mL.

[0078] Solution concentration on a mass basis is 80.25 g/(80.25 g+375 g)=0.1763 g APAP/g solution.

[0079] Air was used as the pressurized fluid in the Bosch Solidlab 1 fluid bed.

[0080] Added 75.73 g of silicon dioxide (Grace Syloid XDP-3150, 150 m particle size) to the Bosch Solidlab 1 fluid bed to form a fluidized cloud of silicon dioxide carrier particles for the processing of a NucleLoad solid dispersion. The bottom spray configuration of the fluid bed was used to spray the acetaminophen solution onto the fluidized cloud of silicon dioxide carrier particles.

TABLE-US-00001 Product Inlet Outlet atomization pattern air Time Temp Temp Temp airflow spray pressure pressure (min) ( C.) ( C.) ( C.) (m{circumflex over ()}3/hr) setting % LEL (bar) (mbar) 0 31.7 45.7 27.3 10 20 0.0 0.7 427 5 31.1 52.6 28.1 10 20 4.9 0.7 427 10 32.3 50.3 28.5 10 20 3.3 0.7 427 15 32.4 50.0 28.6 10 10 6.8 0.7 427 20 32.8 50.0 29.0 10 10 6.0 0.7 427 26 37.4 49.7 31.5 20 15 7.2 0.7 427 31 35.4 43.5 31.6 15 12 5.6 0.7 427 36 33.7 41.6 30.9 15 15 7.1 0.7 427 40 33.0 41.9 30.4 15 15 9.8 0.7 427 45 32.8 42 30.2 15 15 9.8 0.7 427 50 32.7 42.6 30.2 15 18 12.5 0.7 427 55 33.3 45.4 29.9 15 18 13.5 0.7 427 60 33.3 45 29.8 15 20 16.3 0.7 427 65 33.8 44.5 30.0 18 20 14.1 0.88 624 70 35.7 45 30.1 18 22 15.3 0.88 624 75 36.3 45 30.4 18 22 15.3 0.88 624 80 35.6 40.5 29.9 18 22 15.3 0.88 624 85 34.2 39.7 29.4 18 22 15.3 0.88 624 90 33.6 39.9 29.2 18 22 15.5 0.88 624 95 33.2 40.0 29.2 18 22 15.3 0.88 624 97 33.3 40.0 29.2 18 22 15.2 0.88 624 100 34.3 47.2 31.4 18 0 0 0.88 624 103 37 51.3 33.4 18 0 0 0.88 624

[0081] Collected 103.47 g net weight of a dry solid dispersion product (NucleLoad solid dispersion).

[0082] The material was free flowing and suitable for further processing.

[0083] Calculation of solution sprayed: [0084] 146.00 g remaining. [0085] 455.25 g starting quantity. [0086] 309.25 g sprayed. [0087] 309.25 g0.1763 g APAP/g=54.52 g APAP sprayed.

[0088] Yield=100%[103.47 g/(75.73 g+54.52 g)]=79.4%.

TABLE-US-00002 convert to mL conc qty Theoretical g (0.791 g/mL 0.169 APAP qty loading (%) sprayed density) (g/mL) (g) Syloid on a mass basis 309.25 244.62 0.169 41.34 75.73 35.31

[0089] Labeled sample collected as lot 15116-4A (NucleLoad solid dispersion). The resulting theoretical loading is based on an assay of the solid APAP loaded on a mass basis. To calculate the theoretical loading on a volume basis, solid APAP has a density of approximately 1.3 g/mL. 41.34 g of APAP would occupy a volume of 53.74 mL. Syloid silica pore volume is 1.7 mL/g, so 75.73 g of Syloid would have a pore volume of 128.74 mL. Theoretical loading volume=10053.74/128.74=42% on a volume basis.

[0090] FIG. 2 shows an illustration of a silicon dioxide pore using the NucleLoad processing method of Example 1. The pore is substantially filled. The void volume (based on mass) was <5%.

Example 2

Comparative Example A

Evaluate the Processability of Adding the Same Ratio of Ingredients as was Performed in Example 1, but Without the Use of the Fluid Bed

[0091] Added 22.02 g of an acetaminophen/methanol solution to 7.5 g silicon dioxide (Grace Syloid XDP-3150-150 m particle size). The silicon dioxide/acetaminophen/methanol solution became saturated (and particles came out of solution). This material was not processable (and could not be fluidized in a fluid bed).

[0092] FIG. 3 shows a photograph of the saturated solution made with the processing method of Example 2.

Example 3

Comparative Example B

Calculate Loading Efficiency of Example 2 Based on Pore Volume

[0093] The following example was performed at 1/10.sup.th of the scale of Example 1 for comparative purposes.

[0094] 7.5 g of Syloid XDP-3150 contains 1.7 mL pore volume per gram=12.75 mL.

[0095] 12.75 mL to fill with 0.791 g/mL density solution=10.09 g theoretical solution volume.

[0096] Added 10.78 g of an acetaminophen/methanol solution to the Syloid XDP-3150 and a wet paste was formed.

[0097] Dried the paste in an oven on a pan at 60 C. overnight (approx. 15-16 hours).

[0098] Labeled sample as 15116-4C (conventional process solid dispersion).

[0099] FIG. 1 shows a picture of a silicon dioxide pore using the conventional processing method of Example 3. The evaporated solvent left a partially filled pore. The void volume (based on mass) was >50%.

[0100] A comparison of FIG. 1 (void volume in Example 3 conventional solid dispersion) to FIG. 2 (void volume in Example 1 NucleLoad solid dispersion) shows the superior loading efficiency of the NucleLoad process.

Theoretical Loading Conc.

[0101]

TABLE-US-00003 Soln conc (mg/mL) Soln vol (mL) Qty APAP (mg) Solids Loading % 169 12.75 2154.75 22.32

[0102] To calculate the theoretical loading on a volume basis, solid APAP has a density of approximately 1.3 g/mL. 2.154 g of APAP would occupy a volume of 2.80 mL. Syloid pore volume is 1.7 mL/g, so 7.5 g of Syloid would have a pore volume of 12.75 mL. Theoretical loading volume=1002.154/12.75=17% on a volume basis.

Example 4

Analysis of Sample Content of Example 1 (NucleLoad Solid Dispersion) vs. Example 3 (Conventional Solid Dispersion) by Denovix UV-Vis Spectrometer

[0103]

TABLE-US-00004 Weight of volume of APAP APAP (mg) methanol (mL) Concentration 3.0 1.5 2 0.5 mL of above = 1 mg 0.5 1 0.5 mL of above = 0.5 mg 0.5 0.5 0.5 mL of above = 0.25 mg 0.5 0.25

TABLE-US-00005 Reference Curve from Denovix UV-Vis Detector mg/mL 248 nm 249 nm 250 nm 0.25 13.27 13.26 13.16 0.5 31.65 31.66 31.51 1 59.98 60.03 59.62 2 123.79 123.83 123.15 Solve for quantity % measured using 249 mL mg mass loading Sample 249 nm nm solvent mg sample concentration Example 1 80.87 1.32 4 5.26 18 29.25 1.44 increase 15116-4A over 15116-4C Example 3 42.58 0.70 4 2.82 13.9 20.25 15116-4C

[0104] The % measured loading concentration on a mass basis for Example 1 was 29.25%, which is considerably higher than the 20.25% measured loading concentration for Example 3. This is a significant finding because the NucleLoad process used in Example 1 achieved a 44% increase in the loading efficiency of acetaminophen over the conventional method used in Example 3, where the pore volume of the silicon dioxide limits the quantity of solvent and solids that can be added. As mentioned above, the volume occupied by the solvent after it evaporates creates a void space, which can increase the amount of entrapped air in a formulation. Entrapped air in a solid dosage formulation has been attributed to tableting defects, such as splitting and capping of the tablet matrix. The NucleLoad process of Example 1 minimized entrapped air by simultaneously removing the solvent while adding solid to the silicon dioxide pore volume.

Example 5

Loading of Curcumin on Silicon Dioxide Using Bosch Solidlab I Fluid Bed

[0105] Solid crystalline curcumin (PureBulk, Inc., Roseburg, Oreg.) was purchased for use as a raw material. The process described in this example was used to create a NucleLoad intermediate (NLI) comprising amorphous curcumin, which was further processed into a tablet by downstream processes. The NLI was isolated prior to the additional processing steps.

[0106] Composition of a curcumin solution is provided in the table below.

TABLE-US-00006 % 600 g Actual Ingredient Comments w/w batch Dispensed (g) Curcumin Curcumin Extract Lot 1 6 6.03 20170816-03-0250g Solutol HS15 5 30 30.62 Plasdone K-29/32 4 24 24.01 Ethanol 90 540 602.4 100

[0107] Added 6.03 g curcumin, 549.5 g ethanol and 30.62 Solutol HS15 (Kolliphor HS15) (BASF Pharmaceuticals) (BASF USA, Florham Park, N.J.) into a 1-L media bottle, and stirred the composition on a magnetic stir plate. [0108] Start stirring: 2:45 pm, added 52.9 g ethanol until 2:49 pm. [0109] Start sonicating: 3:04 pm. [0110] Stop sonicating: 3:24 pm.

[0111] Added Plasdone K-29/32 (Ashland Inc., Covington, Ky.). [0112] Start mixing: 3:25 pm. [0113] Stop mixing: 3:49 pm.

[0114] Air was used as a pressurized fluid in the Bosch Solidlab 1 fluid bed.

[0115] Added 35.07 g of silicon dioxide (Grace Syloid XDP-3150-150 m particle size) to the Bosch Solidlab 1 fluid bed to form a fluidized cloud of silicon dioxide carrier particles for the NucleLoad processing of a solid dispersion. Used the bottom spray configuration to spray the curcumin solution onto the fluidized cloud of silicon dioxide carrier particles.

TABLE-US-00007 pattern Product Inlet Outlet spray Spray atomization air Time Temp Temp Temp airflow setting % amount pressure pressure (min) ( C.) ( C.) ( C.) (m{circumflex over ()}3/hr) (%) LEL (g) (bar) (mbar) 0 44.1 49.5 39.3 34 20 0 0 0.84 649 5 45.0 54.2 38.8 33 20 4.1 13.20 0.84 647 8 48.2 60.2 40.5 33 30 9.4 23.46 0.84 648 10 48.6 60.9 40.6 32 40 11.2 29.70 0.84 649 14 49.0 60.9 40.3 31 40 17.9 56.70 1 714 18 49.5 60.9 40.3 30 50 24.0 81.75 1 712 20 50.5 64.2 39.7 29 50 26.2 98.97 1 712 25 52.2 64.6 406 34 50 20.8 143.55 1 709 29 51.7 64.5 41.5 34 55 24.9 174.72 1 707 30 51.5 64.7 41.5 34 55 24.1 182.23 1 709 34 51.9 65.2 41.9 34 60 26.3 225.19 1 707 35 51.7 65.2 41.6 34 60 25.3 240.93 1 707 40 51.6 65.0 41.6 34 60 28.2 281.00 1 707 45 54.6 60.7 47.1 34 60 0 297.70 1 704 50 50.9 59.7 42.6 34 60 16.2 328.99 1 706 55 50.0 59.8 42.2 34 60 28.4 371.90 1 704 60 49.9 60.1 40.9 34 60 27.6 411.10 1 704 65 52.0 63.2 41.7 34 60 27.1 463.31 1 703 70 53.3 63.1 42.0 34 60 26.6 513.64 1 705 75 53.6 63.0 42.2 34 60 26.6 561.29 1 703 80 53.4 63.1 42.6 34 60 26.2 618.09 1 703 86 (stop) 53.1 63.0 43.5 34 60 0 656.67 1 703 Dried for 5 minutes then turned off to cool. Cool in chamber overnight

[0116] Collected 71.96 g of NucleLoad curcumin amorphous intermediate out of 95 g theoretical.

[0117] Yield is 10071.96/95=75.75%.

[0118] Standard solutions were generated by dissolving solid crystalline curcumin (PureBulk) in methanol and measuring the solutions on a Denovix UV-Vis detector to generate a calibration curve to determine curcumin concentrations in the samples. Started with most concentrated by adding 1.1 mg into 1.0 mL of methanol. Pipetted 500 L of 1.1 mg/mL solution into a new HPLC vial and diluted with 500 L of methanol to create 0.55 mg/mL solution. Repeated successive dilution scheme as detailed in the table below.

TABLE-US-00008 Curcumin conc Absorbance at (mg/mL) 425 nm 0.06875 9.7935 0.1375 21.4291 0.275 38.0285 0.55 64.01 1.1 116.2395

[0119] A calibration curve for dissolved crystalline curcumin UV absorbance (Abs) as a function of concentration was calculated from the equation of conc=0.0099Abs0.0671 with an R-squared coefficient of 0.99532. This equation was used for the samples in table below.

Determined Concentrations in the Samples Below.

[0120]

TABLE-US-00009 Conc = Abs 0.0099 0.0671 Concentration Abs at 425 nm (mg/mL) Crystalline curcumin 0.0658 Below limit of in water t = 1 hr quantitation NucleLoad 134.6935 1.27 Intermediate of curcumin (Example 5) in water t = 1 hr 50:50 NucleLoad Inter- 64.889 0.575 mediate of curcumin (Example 5) in water 28.8 mg NucleLoad Inter- 74.37 0.669 (or 1.67 mg in mediate of curcumin (Example 2.5 mL) 5) in 2.5 mL methanol concentration NucleLoad Intermediate of 24.6 0.18 curcumin (Example 5) in water 20 hour Crystalline curcumin in water 0.1945 Below limit of 20 hour quantitation

[0121] Theoretical concentration of NucleLoad Intermediate is 6.316%.

[0122] Actual measured % concentration is 1.67 mg/28.8 mg=5.800%.

[0123] Adjusted Assay is 5.800%/6.316%=91.8%.

[0124] FIG. 4 shows X-ray powder diffraction patterns of a commercial (PureBulk) solid crystalline curcumin and an amorphous solid dispersion of curcumin using the NucleLoad processing method of Example 5. This figure confirms the amorphous nature of the curcumin NLI as compared to the commercial crystalline curcumin used in the preparation of the NLI.

Example 6

Formulation of an Amorphous NucleLoad Final Product from the NLI of Example 5 and Compression Into 24 mg Tablets

[0125] The formulation composition is provided in the table below.

[0126] A physical mixture was prepared by blending all the ingredients, except for magnesium stearate, for 5 minutes at 25 rpm.

[0127] Added magnesium stearate and blended for an additional 3 minutes at 25 rpm to form an amorphous NucleLoad final blended product. The NucleLoad final blended product exhibited good flow properties, without the need for additional granulation processing, such as roller compaction. This was advantageous with respect to processing cycle times and efficiency.

TABLE-US-00010 Adjust for 91.8% Theoretical assay for 24.3 mg dose Concentration qty for Actual % mg/ % mg/ 25 g Qty Ingredient w/w tablet w/w tablet batch Weighed Example 5 NLI 76.0 380 83.924 419.6 20.98 20.98 Mixture Microcrystalline 21.0 105 13.076 65.4 3.27 3.27 Cellulose (Avicel PH102) Croscarmellose 2.0 10 2.000 10.0 0.50 0.51 Sodium (Ac-Di-Sol) Mg Stearate 1.0 5 1.000 5.0 0.25 0.25 (Ligamed) 100.0 500 100 500 25 25.01

[0128] Compressed the NucleLoad final blended product into 24 mg tablets using a Korsch PH100 rotary tablet press. Labeled sample as lot 15116-6.

Equipment for Analyzing Tablets.

[0129] Analytical balance for weight determination; Mitutyo micrometer for tablet thickness; and Vankel VK200 hardness tester.

TABLE-US-00011 Tablet compression weight (mg) thickness (mm) hardness (kp) (7.5 17 mm tooling) (n = 10) (n = 10) (n = 5) Average 506.1 5.77 5.3 Std Dev 5.8 0.0 0.5 RSD % 1.1 0.4 9.8

Example 7

Comparison of NucleLoad Amorphous Curcumin 24 mg Tablet to a Commercial Crystalline Curcumin 200 mg CapsuleDissolution and Disintegration

[0130] The dissolution and disintegration of the NucleLoad curcumin tablet (lot 15116-6) of Example 6 (24 mg) was simultaneously monitored with a Focused Beam Reflectance Measurement (FBRM) device (METTLER TOLEDO Lasentec, Model S400) and a UV detection device (Denovix) at 415 and 425 nm.

[0131] Filled a 100 mL beaker with 60.1 g purified water.

[0132] Added tablet to the water with a mesh tablet holder to the beaker on the Model S400 FBRM fixed beaker stand. Simultaneously measured FBRM with fine electronics at 2 m/s scan speed while pulling samples for dissolution analysis.

[0133] Analyzed solution concentration by UV absorption with Denovix UV-Vis detector. A slight shift in the peak of curcumin to 415 nm in water was observed. Used 415 nm for calculations. 425 nm values were recorded for comparison.

TABLE-US-00012 Time Concentration Quantity of Curcumin (min) 425 nm 415 nm Calc. (mg/mL) in 60.1 mL water 5 8.4569 8.6145 0.018 1.093 10 16.4082 16.4916 0.096 5.780 15 20.9786 21.085 0.142 8.513 20 24.3282 24.3327 0.174 10.445 25 24.1572 24.0697 0.171 10.288 30 23.4813 23.5672 0.166 9.990

[0134] The dissolution and disintegration of the NucleLoad amorphous curcumin product produced by Example 6 will now be compared to the dissolution and disintegration of a commercially available capsule formulation containing 200 mg of crystalline curcumin with turmeric essential oil. The tradename of a commercial capsule is CuraMed (manufacturer lot 170501) and can be purchased from Terry Naturally (Green Bay, Wis.). Simultaneous monitoring was accomplished via FBRM and UV detection at 415 and 425 nm.

[0135] Filled a 100 mL beaker with 60.4 g purified water.

[0136] Added capsule to the water with a mesh tablet holder to the beaker on the Model S400 FBRM fixed beaker stand.

[0137] Simultaneously measured FBRM with fine electronics at 2 m/s scan speed while pulling samples for dissolution analysis.

[0138] Analyzed solution concentration by UV absorption with Denovix UV-Vis detector. A slight shift in the peak of curcumin to 415 nm in water was observed. Used 415 nm for calculations. 425 nm values were recorded for comparison.

[0139] The CuraMed commercial capsule formulation (200 mg of curcumin) was advertised with claims to be up to 500 times stronger than tumeric and was characterized as providing superior absorption curcumin.

TABLE-US-00013 Time Concentration Calc Quantity of Curcumin (min) 425 nm 415 nm (mg/mL) in 60.1 mL water 5 0.0542 -0.0312 below limit of below limit of quantitation quantitation 10 0.3260 0.4932 below limit of below limit of quantitation quantitation 15 0.1279 0.1344 below limit of below limit of quantitation quantitation 20 0.2605 0.1112 below limit of below limit of quantitation quantitation 25 1.3023 1.2211 below limit of below limit of quantitation quantitation 30 0.2232 0.1916 below limit of below limit of quantitation quantitation

[0140] FIG. 5 shows the dissolution profiles of the commercial CuraMed crystalline curcumin (200 mg) capsule of Example 7 and the NucleLoad solid dispersion amorphous curcumin (24 mg) tablet of Example 6. A comparison of the dissolution profiles of the formulations shows there was a significant increase in dissolution of curcumin for the NucleLoad solid dispersion tablet.

[0141] FIG. 6 shows a focused beam reflectance measurement (FBRM) total count profile of the commercial CuraMed crystalline curcumin (200 mg) capsule of Example 7 and the NucleLoad solid dispersion amorphous curcumin (24 mg) tablet of Example 6. The FBRM analysis shows distinct property differences between the two formulations. The commercial CuraMed curcumin capsule formulation exhibited a higher particle count, indicating lack of dissolution of particles. In contrast, the NucleLoad solid dispersion curcumin tablet exhibited a lower particle count, indicating more soluble particles, which can enhance performance characteristics.

[0142] A table showing binned chord length FBRM statistics for NucleLoad solid dispersion amorphous curcumin 24 mg tablets at 5 minute intervals is provided below.

TABLE-US-00014 00:05:03 00:10:03 00:15:01 00:20:03 00:25:03 00:30:03 Trend (Fine) (Fine) (Fine) (Fine) (Fine) (Fine) Mean No Wt 37 36 36 34 34 33 Mean Lth Wt 81 84 78 81 79 76 counts No 576 1084 1388 1698 1834 1895 Wt 1-1000 counts No 176 344 428 538 593 631 Wt 1-10 counts No 247 468 609 768 821 837 Wt 10-50 counts No 120 211 271 302 329 336 Wt 50-110 counts No 32 59 79 88 89 90 Wt 110-300 counts No 0 2 1 2 2 1 Wt 300-1000

[0143] A table of binned chord length FBRM statistics for commercial CuraMed crystalline curcumin 200 mg capsules at 5 minute intervals is provided below.

TABLE-US-00015 00:05:09 00:10:00 00:15:00 00:20:04 00:25:04 00:30:02 Trend (Fine) (Fine) (Fine) (Fine) (Fine) (Fine) Mean No Wt 19 33 31 30 29 29 Mean Lth Wt 69 66 67 64 62 59 counts No 36 9539 11130 12004 12408 12596 Wt 1-1000 counts No 14 1724 2158 2456 2732 2610 Wt 1-10 counts No 21 6116 7143 7710 7884 8254 Wt 10-50 counts No 0 1410 1520 1549 1535 1482 Wt 50-110 counts No 0 277 290 272 239 236 Wt 110-300 counts No 0 12 19 17 19 13 Wt 300-1000

[0144] A comparison of the tables for the two formulations shows that the CuraMed crystalline capsule formulation exhibited a higher count for each particle range. This further supports our analysis that the NucleLoad solid dispersion amorphous curcumin tablet formulation provides significantly improved solubility of the contents over time.

Example 8

Spray Drying of a Curcumin Formulation Using a Buchi Spray Dryer

[0145] Commercial crystalline curcumin (PureBulk) was purchased for use as a raw material. The process described in this example is used to create a spray dried amorphous intermediate from a commercial crystalline curcumin starting material. The intermediate was isolated prior to additional processing steps to produce a tablet or capsule formulation.

[0146] The composition of a curcumin spray solution is provided in the table below.

TABLE-US-00016 Actual Bottle + % 60 g Dispensed stir bar Lot Expiration w/w batch (g) Tare (g) Curcumin Curcumin Extract 0.91 0.546 0.5460 170.12 Lot 20170816- 03-0250g Solutol Kolliphor HS-15 4.62 2.772 2.77 HS15 (Sigma) Plasdone 1590176 3.62 2.172 2.1721 K-29/32 Reagent 17E176504. 04/2022 90.85 54.51 54.52 Alcohol (Ethanol) Total Solids 9.15 5.49 60.01

[0147] Added 0.5460 g curcumin into 54.52 g of ethanol and mixed for 10 minutes.

[0148] Added 2.1721 g of Plasdone K29/32 to solution.

[0149] Mixed on a stir plate for 6 minutes.

[0150] Solution became a clear bright orange solution.

[0151] Buchi spray drying with a two-fluid nozzle was performed using the processing parameters in the table below.

TABLE-US-00017 Actual Final bottle Set Inlet Inlet Outlet Pump Spray Gas Bottle + after Time Temp. Temp. Temp. Rate Ballance Flow material spraying (hh:mm:ss) ( C.) ( C.) ( C.) (%) (g) (mm) (g) (g) 00:00:00 130 130 68 20 0 40 229.56 169.80 00:01:00 130 131 68 20 8.58 00:02:00 130 129 68 20 11.43 0.8748 15.93 00:03:00 130 129 68 20 15.25 00:04:00 135 129 69 20 18.12 00:05:00 135 136 72 20 26.34 00:06:00 130 131 68 20 8.09 40 00:08:00 130 130 69 20 00:10:10 130 130 71 15

[0152] A significant amount of material adhered to the side walls of the cyclone chamber was observed. The material on the walls was a dark blood orange. The material in the collection vessel was bright orange. Scraped off material on the walls of the cyclone and mixed it in with the material deposited in the collection vessel. Dried the collected powder in a 60 C. oven overnight (approximately 16 hours) to remove any residual solvent.

[0153] The yield is calculated below.

TABLE-US-00018 Total Container Weight Before Spraying (g) 229.56 Total Container Weight After Spraying (g) 169.80 Amount Sprayed (g) 59.76 Solids Loading 0.07 Wet Recovered Product (g) 0.8748 Wet Yield (%) 15.9% Dry Recovered Product (g) 0.8562 Dry Yield (%) 15.6% % Loss of Drying 2.1%

[0154] A 15.6% dry yield is consistent for the spray drying process and reflects the observation whereby a significant amount of product was stuck to the processing chamber.

[0155] FIG. 7 provides an X-ray powder diffraction pattern of the amorphous solid dispersion of curcumin spray dried intermediate using the processing method of Example 8.

[0156] As shown in the figure, there are sharp peaks around 19 and 23 2-theta degrees indicating the presence of crystalline material in the sample. This is an important finding because spray drying (a common method of producing amorphous dispersions) did not fully convert the crystalline curcumin into an amorphous form. In contrast, the novel NucleLoad process detailed in Example 5 converted the curcumin into a substantially full amorphous powder (FIG. 4) with the added benefit of providing a significantly higher yield than the spray drying process of Example 8.

Example 9

Storage Stability Testing of Example 5 and Example 8

[0157] The amorphous curcumin solid dispersions of Example 5 and Example 8 were stored and tested for stability.

[0158] FIG. 8 presents a photographic comparison of the amorphous solid dispersion of curcumin using the NucleLoad processing method of Example 5 after storage for 3 weeks at 40 C./75% RH and the amorphous solid dispersion of curcumin using the conventional spray drying processing method of Example 8 after storage for 24 hours at 40 C./75% RH. This figure shows that the spray dried solid dispersion of Example 8 possesses inferior solid state stability compared to the NucleLoad solid dispersion of Example 5. The sample of Example 8 melted onto the sample tray into a glassy substance. It could not be isolated as a powder or processed further into a tablet or capsule. In stark contrast, the NucleLoad sample of Example 5 remained in a stable powder form after 3 weeks storage at 40 C./75% RH conditions, which are generally considered to be aggressive storage conditions for an amorphous solid dispersion.

[0159] While specific embodiments have been described above with reference to the disclosed embodiments and examples, such embodiments are only illustrative and do not limit the scope of the invention. Changes and modifications can be made in accordance with ordinary skill in the art without departing from the invention in its broader aspects as defined in the following claims.

[0160] All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. No limitations inconsistent with this disclosure are to be understood therefrom. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.